Accesso Technology (ACSO LN) FY 2015 results comfortably ahead, upgrades likely | Advanced Medical Solutions (AMS LN) In line prelims and positive market backdrop | EMIS Group (EMIS LN) In line results, questions remain on outlook | Restore (RST LN) Opportunity & firepower to continue industry roll-up | Summit Therapeutics (SUMM LN) Biomarker publication better informs PhaseOut clinical trial | Tribal Group (TRB LN) New chapter begins| Xaar (XAR LN) 2016 upgrade; 2017 downgrade on R&D treatment
16 Mar 2016
Morning Song
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Song
accesso Technology Group Plc (ACSO:LON), 609 | Advanced Medical Solutions Group plc (AMS:LON), 192 | Restore plc (RST:LON), 225 | Tribal Group plc (TRB:LON), 54.5 | Xaar plc (XAR:LON), 117 | Summit Therapeutics Inc (SMMT:NAS), 0
- Published:
16 Mar 2016 -
Author:
N+1 Singer Team -
Pages:
14
Accesso Technology (ACSO LN) FY 2015 results comfortably ahead, upgrades likely | Advanced Medical Solutions (AMS LN) In line prelims and positive market backdrop | EMIS Group (EMIS LN) In line results, questions remain on outlook | Restore (RST LN) Opportunity & firepower to continue industry roll-up | Summit Therapeutics (SUMM LN) Biomarker publication better informs PhaseOut clinical trial | Tribal Group (TRB LN) New chapter begins| Xaar (XAR LN) 2016 upgrade; 2017 downgrade on R&D treatment